All Oncology News

The top 5 OncLive TV videos of the week cover insights in head and neck cancer, esophageal cancer, renal cell carcinoma, and breast cancer.

Rena D. Callahan, MD, discusses clinical considerations for CDK4/6 inhibitor–based regimens and oral SERDs in hormone receptor–positive breast cancer.

The FDA grants priority review to enfortumab vedotin-ejfv sBLAs in MIBC, the review period for subcutaneous isatuximab BLA in myeloma has been extended, and more.

Data from a real-world analysis demonstrated the efficacy and safety of CAR T-cell therapy in primary mediastinal B-cell lymphoma.

Translational analyses from NEOPRISM-CRC also link ctDNA clearance/kinetics and TCR clonality with pCRs, supporting biomarker-guided treatment selection.

Fecal microbiota transplantation extended median PFS with first-line pembrolizumab plus axitinib in metastatic RCC.

Ris-rez plus adebrelimab led to an approximate 50% response rate and durable disease control in pretreated nonsquamous NSCLC without actionable mutations.

Researchers at Roswell Park Comprehensive Cancer Center developed a two‑step therapeutic strategy designed to selectively eliminate tumors driven by TP53 mutations.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Darlifarnib plus cabozantinib showed preliminary activity and safety across dose levels in cabozantinib-treated ccRCC.

With approximately 3 years of follow-up, TKI-naive patients with ROS1+ NSCLC experienced long-term benefits with taletrectinib.

Phase 1/2 data from 2 separate studies have shown signals of improved survival and safety with the agent, supporting its evaluation in a phase 3 trial.

Colton Jones, MD, and Joel Saltzman, MD, discuss the potential role of GLP-1 receptor agonists in CRC prevention based on retrospective data.

A Mayo Clinic study helped clarify how immune-related kidney inflammation develops and provided preclinical evidence on a targeted approach to mitigate these adverse effects.

Tafasitamab in combination with rituximab and lenalidomide has been approved for relapsed or refractory follicular lymphoma in Australia.

Amivantamab plus lazertinib improves second-line PFS vs osimertinib in EGFR-mutant NSCLC, per post hoc data from MARIPOSA presented at AACR 2026.

Early evidence suggests a dual bispecific strategy may be able to move the needle forward for patients with platinum-resistant ovarian cancer or endometrial cancer.

The brain-penetrant, noncovalent EGFR TKI produced an ORR of 87.5% in 8 efficacy-evaluable patients with EGFR-mutant NSCLC.

The fourth-generation EGFR C797S inhibitor ABK-EGFR-1 showed promising in vivo efficacy in various EGFR C797S mutation models.

Tovorafenib has received conditional marketing authorization in Europe for patients at least 6 months of age with BRAF-positive relapsed/refractory pLGG.

A new UCLA study suggests the organization of immune cells inside melanoma tumors may help show which patients benefit from combination immunotherapy

The FDA has extended the target action date to review a BLA seeking the approval of subcutaneous isatuximab for multiple myeloma.

A response to neoadjuvant chemotherapy was associated with long-term survival benefits in high-risk UTUC.

Sac-TMT produced durable responses with a manageable safety profile in pretreated advanced/metastatic urothelial carcinoma.

Post-treatment ctDNA positivity was associated with disease recurrence in locoregionally advanced HNSCC, including p16-positive oropharynx cancer.

The 5-year OS rate favored tebentafusp vs investigator’s choice of therapy in HLA-A*02:01–positive uveal melanoma.

Toni Choueiri, MD, of Dana-Farber Cancer Institute, was elected to The Association of American Physicians.

Pembrolizumab plus lenvatinib and belzutifan, as well as pembrolizumab/quavonlimab plus lenvatinib, did not extend OS or PFS in first-line ccRCC.

Maurie Markman, MD, highlights the frequently complex arena of goals of care discussions in oncology.

China’s NMPA approved belantamab mafodotin plus Vd for the treatment of relapsed/refractory multiple myeloma after at least 1 prior line of therapy.